Humacyte (NASDAQ:HUMA) Director Kathleen Sebelius Buys 56,818 Shares of Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Kathleen Sebelius acquired 56,818 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was acquired at an average cost of $0.88 per share, for a total transaction of $49,999.84. Following the completion of the acquisition, the director owned 148,025 shares of the company’s stock, valued at $130,262. This trade represents a 62.30% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Humacyte Stock Up 11.1%

Shares of HUMA opened at $0.92 on Thursday. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46. Humacyte, Inc. has a 12 month low of $0.55 and a 12 month high of $2.93. The stock’s 50 day moving average is $0.84 and its two-hundred day moving average is $1.04. The firm has a market cap of $203.64 million, a P/E ratio of -1.61 and a beta of 2.31.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.46 million. Analysts predict that Humacyte, Inc. will post -0.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the company. Wall Street Zen raised Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday, April 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research note on Friday, April 10th. BTIG Research lowered their price target on Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Finally, Benchmark lowered their price target on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Humacyte presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.57.

Hedge Funds Weigh In On Humacyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. R Squared Ltd acquired a new position in Humacyte during the fourth quarter worth $25,000. Atom Investors LP acquired a new position in Humacyte during the fourth quarter worth $25,000. Truist Financial Corp acquired a new position in Humacyte during the third quarter worth $28,000. Prudential Financial Inc. acquired a new position in Humacyte during the second quarter worth $28,000. Finally, Financial Advisors Network Inc. acquired a new position in Humacyte during the second quarter worth $28,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.